Accelerating the fight against malaria
Malaria is second only to tuberculosis in terms of its devastating global impact. The disease killed an estimated 627,000 people in 2020, mostly children under five.
Existing malaria vaccines only target the first stage of the parasite’s life cycle and have limited efficacy. A vaccine effective at every stage of the life cycle would help prevent transmission of the disease – as well as protecting those exposed.
AlphaFold has helped researchers understand the full-length structure of a critical protein related to the disease. This breakthrough has marked a turning point in their work, enabling further research into a transmission-blocking vaccine to help combat malaria.
Research credits
- Professor Matthew Higgins, University of Oxford
- National Institute of Allergy and Infectious Diseases, USA